Diet Education Program for Stage I-IV Colorectal Cancer Survivors

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT04597151
Collaborator
(none)
13
1
1
10.6
1.2

Study Details

Study Description

Brief Summary

This pilot trial evaluates the feasibility of a group diet education program for stage I-IV colorectal cancer survivors. Providing a nutrition education program for colon and rectal cancer survivors may help them have better access to the tools necessary to make healthy food decisions that can impact their cancer outcomes.

Detailed Description

PRIMARY OBJECTIVE:
  1. To describe the feasibility and acceptability of a group diet education intervention for colorectal cancer (CRC) survivors at Zuckerberg San Francisco General Hospital (ZSFGH).
SECONDARY OBJECTIVE:
  1. To describe perceived barriers to healthy diet among CRC survivors at ZSFGH.
EXPLORATORY OBJECTIVES:
  1. To evaluate for differences in feasibility and acceptability of a group diet education program, based on sociodemographic factors such as education, food insecurity, employment, and race.

  2. To explore changes in health-related behaviors pre and post intervention using a validated lifestyle score.

OUTLINE:

Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).

After completion of study, patients are followed up at 12 weeks.

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Diet Education Among Colorectal Cancer Survivors in the Safety Net Setting: A Pilot Feasibility Study
Actual Study Start Date :
Oct 12, 2020
Actual Primary Completion Date :
Aug 31, 2021
Actual Study Completion Date :
Aug 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Supportive care (diet education)

Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).

Dietary Supplement: Dietary Intervention
Attend diet education sessions
Other Names:
  • Dietary Modification
  • intervention, dietary
  • Nutrition Intervention
  • Nutrition Interventions
  • Nutritional Interventions
  • Outcome Measures

    Primary Outcome Measures

    1. Percentage of participants missing questionnaires [Up to 17 weeks]

      Feasibility of measurement tools will be assessed by reporting the percentage of participants whom did not complete the questionnaires

    2. Follow-up response rates [Up to 17 weeks]

      Feasibility of measurement tools will be assessed by follow up response rates (week 6 and week 17)

    3. Frequency of reasons for not participating in questionnaires [Up to 17 weeks]

      Feasibility of measurement tools will be assessed by recording and reporting reasons for not taking part in questionnaires.

    4. Number of participants who consent or expressed interest [Up to 17 weeks]

      Subject recruitment will be assessed by number of participants who consent/number of participants who initially expressed interest, and reasons for non-participation will be documented.

    5. Percentage of consented patients who remain on the study [Up to 17 weeks]

      Subject retention will be assessed by percentage of consented patients who remain on the study at week 6 and at week 17, and reasons for dropout will be documented.

    6. Number of sessions attended [Up to 17 weeks]

      Adherence to diet education intervention will be assessed by number of sessions attended and reasons for absence will be documented.

    7. Categorical responses to program evaluation survey [Up to 17 weeks]

      Experience (e.g. satisfaction) will be assessed by tabulated responses to program evaluation survey. Qualitative analysis of cleaned and coded transcripts from interviews using a "constant comparison" process through which data are built into conceptual categories and themes will be performed.

    Secondary Outcome Measures

    1. Frequency of responses to the baseline socio-demographics survey [Up to 17 weeks]

      Barriers to healthy diet will be described using tabulated responses to the baseline socio-demographics survey and qualitative analysis of coded transcripts from baseline and exit interviews.

    Other Outcome Measures

    1. Change in Lifestyle Score on the National Institute of Health (NIH)/ National Cancer Institute (NCI) Automated Self- Administered 24-hour Dietary Assessment Tool (ASA24) [Up to 17 weeks]

      The ASA24® Dietary Assessment Tool is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries. The ASA24 system consists of a respondent website used to collect dietary intake data and a researcher website used to manage study logistics and obtain nutrient and food group data files to obtain analysis files for 65 nutrients and 37 food groups. This data is used to generate a standardized lifestyle score pre- and post-intervention with possible range: 0-7, based on participant's body mass index and intake of fruits and vegetables, fiber, ultra-processed foods, red meat, processed meat, sugar-sweetened drinks, and alcohol. This standardized score quantifies the degree to which participants' lifestyles are consistent with the 2018 World Cancer Research Fund (WCRF) / American Institute of Cancer Research (AICR) Recommendations.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Able to speak and read English or Spanish

    • Diagnosed with stage 1- 4 colorectal cancer within 5 years prior to study enrollment and treated with curative intent

    • Receiving survivorship follow up care at Zuckerberg San Francisco General Hospital (ZSFGH)

    • Able to provide written consent

    Exclusion Criteria:
    • Currently receiving chemotherapy, biologic therapy, radiation, or immunotherapy for colorectal cancer

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zuckerberg San Francisco General Hospital San Francisco California United States 94110

    Sponsors and Collaborators

    • University of California, San Francisco

    Investigators

    • Principal Investigator: Sorbarikor Piawah, MD, University of California, San Francisco

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of California, San Francisco
    ClinicalTrials.gov Identifier:
    NCT04597151
    Other Study ID Numbers:
    • 204511
    • NCI-2020-06808
    First Posted:
    Oct 22, 2020
    Last Update Posted:
    Feb 1, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 1, 2022